A potential strategy to selectively target FRβ+ AML cells has been pioneeringly described by Lynn et al., developing a high-affinity FRβ-specific chimeric antigen receptor (CAR)-T cells capable of eradicating AML and normal myeloid lineage without HSC toxicity [59]. The gene discussed is FOLR2; the disease is acute myeloid leukemia.